Voyageur has budgeted US$2,350,000 for completion of the Bayer project feasibility study and will create a final budget for the integrated iodine and barium drug facility feasibility study
This strategic acquisition enables CORONA Remedies to penetrate deeper into targeted specialty and offer wider accessibility
CDSCO-approved targeted therapy expands precision oncology options for patients with RET-driven lung, thyroid, and other advanced solid tumours
Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Priced at just Rs. 499 for 1-year supply, this initiative is aligned with the vision of Health for All
Subscribe To Our Newsletter & Stay Updated
